Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00514267
Status:
COMPLETED
Last Update Posted:
2015-08-13
First Post:
2007-08-07
Brief Title:
An Open-Label Study of YM155 Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Phase III Multicenter Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the feasibility and safety of administering YM155 in combination with docetaxel
Detailed Description:
This clinical trial is designed to include two parts
Part 1 Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer HRPC ENROLLMENT COMPLETED
Part 2 Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors except HRPC
This registration has been updated to reflect the design requirements of PART 2
Part 1 Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer HRPC ENROLLMENT COMPLETED
Part 2 Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors except HRPC
This registration has been updated to reflect the design requirements of PART 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None